Clinical Trial Update: Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial of low-dose cytarabine for infants with Down syndrome and transient myeloproliferative disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Transient Myeloproliferative Disorder

Drugs mentioned

• CYTARABINE (CYTARABINE)

Snippet

Sponsor: Children's Oncology Group | Conditions: Leukemia | Phase 3 | Status: WITHDRAWN